Amyloid Beta 42/40 Test

Amyloid beta is a small protein fragment produced when a larger protein, called amyloid precursor protein (APP), is cut by enzymes in the brain. Two of the most common forms are amyloid beta 40 (Aβ40) and amyloid beta 42 (Aβ42). While both circulate in the brain and blood, Aβ42 is stickier and more prone to clump together, forming the amyloid plaques that are a hallmark of Alzheimer’s disease. Aβ40, by contrast, is produced in higher amounts and is less likely to form harmful aggregates.

The ratio of Aβ42 to Aβ40 (Aβ42/40) is considered more informative than measuring either protein alone. A lower ratio typically means that Aβ42 is being trapped in plaques within the brain, leaving less of it circulating in the blood or cerebrospinal fluid. This drop in the ratio correlates strongly with amyloid buildup on brain scans and predicts a higher likelihood of developing memory decline and dementia.

Clinically, this ratio is measured in either cerebrospinal fluid (obtained via lumbar puncture) or blood plasma using sensitive techniques such as mass spectrometry or single-molecule immunoassays. In both cases, a reduced Aβ42/40 ratio aligns with amyloid PET scan positivity, the current gold standard for detecting brain amyloid. Plasma-based testing has gained attention because it is less invasive, less costly, and scalable for early detection and clinical trial recruitment.

It is important to note that total amyloid beta levels can vary between individuals. Some people naturally produce more Aβ overall, which makes the ratio more reliable than absolute values. Still, peripheral production of amyloid beta outside the brain, along with technical variability across assays, can influence results, especially in blood tests. This is why combining the Aβ42/40 ratio with other biomarkers, such as phosphorylated tau (p-tau) or glial fibrillary acidic protein (GFAP), improves diagnostic accuracy.